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Abstract 
Human papillomavirus (HPV) is a common sexually transmitted infection in the United States 
and is the cause of most cervical cancers in women, as well as anogenital cancers, oropharyngeal 
cancer, and genital warts in both men and women (Centers for Disease Control [CDC], 2014b). 
The HPV vaccine is recommended for preteen girls and boys to protect against HPV infections 
(CDC, 2011). In line with the goal of Healthy People 2020, the purpose of this evidence-based 
quality improvement (QI) project was to implement a text message reminder system, and 
calculate the completion rate of the 3-dose HPV vaccination series among adolescents in a 
pediatric clinic in a small city in Texas. The results were compared to the vaccination rates from 
a previously used reminder system. The project was of a single-group. pre-test–post-test design. 
Participants were adolescents aged 9–18 years who had begun, or were set to begin, the 3-dose 
HPV vaccine series during the project implementation period (October 2015–April 2016). Data 
from a random review of 100 charts of adolescents reminded using the prior system (prior to 
implementation) for the same vaccine appointments were used for comparison with the new 
reminder system data. Enrollees received up to 3 text message reminders for each appointment. 
They were surveyed to evaluate their preference of a reminder system. Using data from the prior 
system (n = 100), 11% of adolescents completed the three-dose HPV vaccine series compared to 
46.9% from the text messaging system group (n = 49). Both groups showed a better completion 
rate among females.  Based on surveys, 24 (80%) were in favor of text message reminders. This 
project shows that text message reminders offer an effective method of sending appointment 
reminders to increase the initiation and completion rates of the HPV vaccine series. 
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Improving HPV Vaccination Initiation and Completion Rates: A QI Project 
Background 
 HPV is the most common sexually transmitted infection that can spread from person to 
person during unprotected sexual activity, according to the “Morbidity and Mortality Weekly 
Report” (MMWR) by the CDC (2014b). HPV can cause cervical cancer; the most common 
cancer in women around the world (CDC, 2014c). More than 40 HPV types exist that can cause 
mouth and throat infections. Currently among Americans, approximately 79 million are infected 
and 14 million become newly infected each year (CDC, 2014b). 
Because HPV is common, most sexually active men and women can contract at least one 
type of HPV at some point during their lives. While an infected person may not have any signs 
or symptoms, HPV can be transmitted to others. The CDC (2015b) has said that most HPV 
infections cause no symptoms and are self-limiting, but persistent infections can cause serious 
health problems. According to the latest data on HPV-associated cancer statistics (CDC, 2014c), 
each year approximately 33,200 cancers occur due to HPV in the United States, about 20,600 
among females and about 12,600 among males. HPV vaccines are given to prevent certain types 
of HPV infections, like anal, vulvar, and vaginal cancers, while also preventing genital and anal 
warts (American Cancer Society [ACS], 2014.) 
An estimated 510,000 newly diagnosed cervical cancer cases and 288,000 deaths can 
occur globally due to HPV (Saslow et al., 2007). They also mentioned that in the United States, 
anal cancer is diagnosed in approximately 4,000 people annually (620 deaths) with 80% to 90% 
caused by either HPV16 or HPV18. There are approximately 3,570 vulvar cancer cases annually 
(870 deaths), of which 40% are HPV related. The incremental cost of cancer treatment for local 
and regional cancer was $13,935 and $26,174 and by 12 months, it was increased to $15,868 and 
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$30,917, respectively (Subramanian et al., 2010). The estimated lifetime direct medical cost of 
HPV is $1.7 billion (Owusu-Edusei et al., 2013). 
While an HPV vaccine is available, the rates of completion of the vaccine are not 
satisfactory. HPV vaccine coverage was significantly lower than coverage for other routine 
early-adolescent immunizations, with males less likely than females to initiate and/or complete 
the three-dose HPV vaccine series (Donahue, Stupiansky, Alexander, and Zimet (2014). 
Although many of the previous studies have shown high parental acceptance of the HPV 
vaccination, some parents are concerned due to issues like increased risky sexual behavior, the 
possibility of side effects, worries about the cost/benefits of vaccination, efficacy, safety issues, 
age of vaccine administration, lack of physician recommendation, and the vaccine’s link to a 
sexually transmitted infection (Ogilvie et al., 2007; Olshen, Woods, Austin, Luskin, & Bauchner, 
2005; Perkins & Clark, 2013; Waller, 2006; Zimet, Rosberger, Fisher, Perez, & Stupiansky, 
2013.)  
An estimated 45 million doses of vaccine were distributed in the United States after the 
HPV vaccine’s introduction, but vaccine completion rates remain low (Conroy et al., 2009). The 
CDC (2015a) estimated that the analysis of the 2014 National Immunization Survey (NIS) data 
among teens has shown higher rates of HPV vaccination among adolescent females, Blacks, 
Hispanics, or those living below poverty but still noted lower rates for series completion among 
those groups. 
The cost of three doses of Gardasil is approximately $500 including the cost of 
administration (ACS, 2014). The “Vaccines for Children” program by the CDC (2014b) offers 
vaccines at no charge for eligible children. Providing age-appropriate vaccinations to children 
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will help prevent communicable disease and ultimately improve their health, thus reducing the 
cost of health care. 
Problem Statement 
One of the criteria in their STD treatment guideline, the CDC (2015b) suggested that 
providers use prevention counseling to reduce STD/HIV risk. Moreover, in 2011, the use of the 
quadrivalent HPV vaccine, Gardasil (HPV4), for males and females of a certain age range was 
recommended by the Advisory Committee on Immunization Practices (ACIP). Even with an 
effective vaccination available, acceptance and completion rates of the HPV vaccine are low. 
Using the National Immunization Survey Teen Data of 2014, the CDC reported that despite 
showing a slight increase from 2013, only 60% of girls and 41.7% of boys had one dose of the 
HPV vaccine series. Only 39.7% of girls and 21.6% of boys had received the three doses for 
vaccine series completion (CDC, 2015a). Addressing the importance of HPV vaccination and the 
adherence to the three-dose vaccine series is addressed inconsistently in the current pediatric-
practice setting. The use of text message reminders increased the HPV vaccine series completion 
rates in a pediatric practice (Matheson, Derouin, Gagliano, Thompson, & Blood-Siegfried, 
2014). As evidence from the above mentioned studies have suggested, the current reminder 
methods, along with inadequate counseling on the problem and the number of vaccines available, 
may be factors causing the vaccine’s low acceptance and completion rates. This evidence-based 
QI project is based on the hypothesis that proper counseling and text message reminders should 
increase the initiation and compliance rate of the three-dose series HPV vaccination among the 
target population in a selected pediatric clinic in Texas. 
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Review of the Literature 
Vaccine Efficacy 
In two separate studies, one by Schiller, Castellsague, and Garland (2012), and another 
by De Vincenzo, Ricci, Conte, and Scambia, (2013), data demonstrated that both vaccines—
Gardasil, a quadrivalent vaccine containing virus-like particles (VLPs) of HPV types 6, 11, 16, 
and 18, and Cervarix, a bivalent vaccine with VLPs of types 16 and 18—exhibited excellent 
safety and immunogenicity profiles. The studies also found that the vaccines had remarkably 
high and similar efficacy against cervical intraepithelial neoplasia grade 3 (CIN3) in women, but 
Gardasil showed strong protection against genital warts and vulvar/vaginal neoplasia (Schiller et 
al., 2012.) 
 The efficacy of Gardasil was assessed in four clinical trials among 20,800 women 
between the ages of 16 and 26 years. In follow-up studies of vaccines, a decrease in antibody 
titers was found. Studies also noted an initial sharp decline toward reaching a plateau in the long 
term. The data suggest that both HPV vaccines have different levels of cross-protection against 
HPV types, and there is evidence of cross-protection against CIN 2/3 and adenocarcinoma in situ 
(AIS) for combined HPV types 31 and 45 infections for the bivalent vaccine. The authors have 
suggested that immunization against HPV substantially decreases HPV-related disease (Bonanni, 
Boccalini, & Bechini, 2008). 
There is high efficacy (> 90%) for Cervarix and Gardasil against specific HPV infections 
and high-grade cervical intraepithelial neoplasia (CIN 2+) according to Brotherton (2014). 
Brotherton reported that the quadrivalent vaccine had similar levels of efficacy against vaginal 
and vulvar intraepithelial lesions and genital warts. An added benefit of HPV vaccines is that 
they also offer cross-protection against non-vaccine HPV types for people without previous 
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infections. Bivalent HPV vaccines (HPV 16 and 18, Cervarix) appear to be more efficacious 
against non-vaccine HPV types 31, 33, and 45 than the quadrivalent vaccine (Malagón et al., 
2012).  
 The above mentioned randomized clinical trials (RCT) support the evidence regarding 
the effectiveness of HPV vaccines. It is evident that HPV vaccines are effective against HPV 
diseases in men and women, and giving the vaccine doses before becoming sexually active can 
prevent HPV diseases among adolescents.  
Factors Associated With Completion of HPV Vaccine Series 
Most of the studies’ authors have discussed factors for not completing the HPV vaccine 
regimen, such as parental concerns about vaccine safety, cost, fear of side effects, lack of 
education, and physicians not recommending the vaccine. A randomized intervention cross-
sectional survey was conducted among parents to explore HPV vaccine acceptability, the 
influence of educational information, and to discover independent predictors associated with 
HPV vaccine acceptability (Dempsey, 2006). The survey found that providing parents with an 
HPV information sheet did not improve knowledge about HPV and had little effect on HPV 
vaccine acceptability by parents for their children. The survey also found that attitude and life 
experiences were more important factors influencing HPV vaccine acceptability among parents 
Dempsey (2006). Several authors (Caskey, Lindau, & Alexander, 2009; Gold, Naleway, & 
Riedlinger, 2013; Ogilvie et al., 2007) found that a large number of parents mentioned that a 
recommendation by a physician would increase HPV vaccine acceptance. This is similar to 
findings from other authors who suggested that from the parents’ viewpoint, initiation of the 
HPV vaccine would increase if the parents had received a physician’s recommendation 
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(Dempsey, 2006; Gerend, Weibley, & Bland, 2009; Gottlieb et al., 2009; Reiter, Brewer, 
Gottlieb, McRee, & Smith, 2009; Rosenthal et al., 2008; Yeganeh, Curtis, & Kuo, 2010). 
 A study also reported that few participant girls and young women believed that the HPV 
vaccine was protective beyond the actual impact of the vaccine. These participants thought they 
did not need to have Pap smears, were protected against and could worry less about getting all 
STDs, or no longer needed condoms during intercourse (Caskey et al., 2009). It was found that 
vaccine safety was a major concern among many of the parents, enough so not to vaccinate their 
children (Caskey et al., 2009; Fontenot, Collins Fantasia, Charyk, & Sutherland, 2014; Gold et 
al., 2013; Olshen et al., 2005; Perkins & Clark, 2013; Waller, 2006.) A systematic review of 
literature conducted by Holman et al. (2014) on barriers to HPV vaccination among U.S. 
adolescents found that parents most often reported the need for more information before 
vaccinating their children. The same authors found that parents were concerned about the 
vaccine’s effect on sexual behavior, the low perceived risk of HPV infection, social influences, 
irregular preventive care, and vaccine cost. These concerns were also identified as potential 
barriers. 
While there was high parental acceptance of the HPV vaccination, there was also parental 
concerns due to several issues, such as the possibility of side effects, cost and benefits of 
vaccination, efficacy, safety issues, age for vaccine administration, lack of physician 
recommendation, increase in promiscuity, and the vaccine’s link to a sexually transmitted 
infection (Ogilvie et al., 2007; Olshen et al., 2005; Perkins & Clark, 2013; Waller, 2006; Zimet 
et al., 2013). 
Some of the reasons preventing vaccine compliance were unvaccinated respondents’ 
reports of foregoing the vaccine because of reasons such as not being currently sexually active, 
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not being at risk for sexually transmitted infections and being worried about vaccine safety. A 
few studies also reported parental beliefs regarding getting chronic diseases such as autism or 
multiple sclerosis upon receiving the vaccine, weakening of the child’s immune system caused 
by the vaccine, the cost of the vaccine, the issue of health insurance, access to care due to 
transportation issues, and so on (Caskey et al., 2009; Fontenot et al., 2014). 
Participants who had both a regular health care provider and a health care encounter 
during the previous 6 months were associated with vaccine receipt (Caskey et al., 2009). A study 
comparing Latino and non-Latino women found high (73%) acceptance of the HPV vaccine in 
non-vaccinated eligible women who stated that cervical cancer prevention was the primary 
motivation for getting vaccinated (Watts et al., 2009). 
HPV Vaccine Knowledge and Improvement Based on Education 
In other studies reviewed, a majority of parents had heard about HPV and the HPV 
vaccine (Chang et al., 2013; Daley et al., 2010; Gerend et al., 2009; Gottlieb et al., 2009; Hughes 
et al., 2009; Perkins & Clark, 2013; Perkins, Pierre-Joseph, Marquez, Iloka & Clark, 2010; 
Yeganeh et al., 2010). Even though women knew that HPV infections caused cervical cancer, 
only a few knew the association between HPV and genital warts (Chang et al., 2013; Perkins et 
al., 2010). Almost all parents understood that HPV vaccines must be given before HPV exposure 
to be effective, and 95% stated that vaccination must occur before the initiation of sexual activity 
(Perkins et al., 2010). 
More than half of the parents/guardians knew that HPV was sexually transmitted 
(Dempsey, 2006; Gerend et al., 2009; Hughes et al., 2009; Perkins et al., 2010; Yeganeh et al., 
2010). Two sets of authors (Chang et al., 2013; Wegwarth, Kurzenhäuser-Carstens, & 
Gigerenzer, 2014) found that parents did not know whether the HPV vaccine prevented 
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precancerous lesions nor did they know that death from cervical cancer could potentially be 
prevented by being vaccinated. Most of the women knew that abnormal Pap smears and cervical 
cancer were caused by HPV (Chang et al., 2013; Dempsey, 2006; Hughes et al., 2009; Perkins et 
al., 2010; Yeganeh et al., 2010; Ziarnowski, Brewer, & Weber, 2009). Parents who had already 
vaccinated their daughters believed that they were less likely to get cervical cancer; whereas 
those parents yet to vaccinate their daughters said their daughters had higher chances of getting 
cervical cancer and that they preferred to get their children vaccinated (Ziarnowski et al., 2009). 
Regarding the views of the HPV vaccine, parents who intended to vaccinate their 
daughters were grateful for the protection that vaccination afforded their daughters against 
disease, including cervical cancer (Perkins et al., 2010). On the other hand, in a study by 
Fontenot et al. (2014), the subjects had never heard of HPV, did not know about the HPV 
vaccine, and were not aware that the vaccine even existed. There was a disconnect between the 
actual and perceived risks of HPV and barriers to HPV vaccination. 
Text Messaging Reminder System to Improve HPV Vaccine Adherence 
Several studies have suggested that a text messaging reminder system and educational 
brochures can increase HPV vaccine uptake and dose-completion rates. Kharbanda et al. (2011) 
found that text message reminders were an effective intervention to increase timely receipt of 
second and third HPV vaccines of the series. Jacobson and Szilagyi (2005) found that reminder 
recalls were associated with a 5–20% increase in immunization coverage. The researchers 
suggested that the use of more intensive reminders and recalls, along with multiple reminders, 
seemed to be more effective than single reminders. In Szilagyi et al.’s (2013) RCT, the telephone 
reminder/recall system was found to improve adolescent immunization and preventive visits, 
with modest cost and impact. A QI project on text message reminders for the second and third 
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doses of the HPV vaccine at a busy, urban pediatric practice in North Carolina conducted by 
Matheson et al. (2014) had similar findings. The authors suggest that use of text message 
reminders improved HPV vaccine series completion rates in a timely manner in the pediatric 
clinic.  The authors also think that an increased use of smartphones served as a potential 
facilitator for success. There was better efficacy of text message reminders, as there was a 
modest increase in HPV vaccine rates in their respective studies (Stockwell et al., 2012; Rand et 
al., 2014). Both studies also reported that one of the challenges was making sure that patients had 
a working phone number to receive the text messages. Furthermore, Rand et al. (2014) suggested 
that along with the text messaging reminder system, office-based interventions were deemed 
important to improve HPV vaccination rates because of the issue of parental hesitancy to initiate 
HPV vaccination. 
Use of an evidence-based educational-brochure reminder system significantly improved 
HPV vaccine uptake and completion of the dose (Cassidy, Braxter, Charron-Prochownik, & 
Schlenk, 2014.) These authors found that the rate of HPV vaccination improved from 24% to 
75% when they compared historical control groups with an intervention group. They also noted 
that the methods to address issues with parents, such as the likelihood of HPV infection, cervical 
cancer, and its effect on health, can help cue action regarding parents’ decision making on 
vaccines and can significantly improve uptake rates among preteen girls. 
According to Jacobson and Szilagyi (2005), even though the immunization rates for 
children and adults are rising, coverage levels have not reached the maximum goal. Due to low 
immunization rates, it is important to understand and promote interventions that work in primary 
care settings in order to increase immunization coverage. A common theme across immunization 
programs in all nations involves the challenge of determining the denominator of eligible 
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recipients and identifying the best strategy to ensure high vaccination rates through intervention 
strategies involving patient reminders and recall systems. 
Synthesis of Evidence 
Most study findings have suggested that sending timely notifications to families about the 
next HPV vaccine dose, by means of reminder calls or alerts, may motivate adolescents and their 
parents to seek medical care. In most of the research articles, researchers examined the 
effectiveness of the reminder and recall systems, which improved vaccination coverage. Healthy 
People 2020’s objectives are to reduce the proportion of females with HPV infection (U.S. 
Department of Health & Human Services, 2015a) and increase coverage of the HPV vaccine to 
80% (U.S. Department of Health & Human Services, 2015b). Evidence-based literature on HPV 
vaccination suggests that it is critical to focus on effective educational approaches and reminder 
systems to improve the vaccine uptake among the eligible children.  
Nurses and primary care providers should emphasize educating parents and adolescents 
about the HPV vaccine, which will allow greater vaccine acceptance. Vaccine-related education 
for parents and adolescents should include reasons for vaccination, side effects of the 
vaccination, the safety of the vaccine, the vaccine dose, and the timing of the vaccine, age to 
initiate the vaccine, and other vaccine-related information. Saslow et al. (2007) believed that 
educational interventions would increase HPV vaccine compliance rates. They suggested that 
there is a critical need for education of providers, policy makers, parents, adolescents, and young 
women about early detection, cervical cancer prevention, and the need for routine screening even 
after vaccination. 
The majority of the studies used descriptive research designs, of which one was a 
randomized control study. The strength of the evidence in the literature was based on the Johns 
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Hopkins Nursing Evidence-Based Appraisal Guidelines by Dearholt and Dang (2012). The 
strength of evidence was graded on strengths on a Level 1–3 scale, with 1 being the highest and 
3 being the lowest. The evidence was rated on quality as A (high), B (good), and C (low or 
majorly flawed). Overall, the strength of all evidence could be rated as 2 and the quality of 
evidence as a B (good). 
Theoretical Framework 
Based on the necessary organizational change, the Rosswurm and Larrabee (R&L) model 
(Rosswurm & Larrabee, 2007) for guiding nurses through a systematic process for a change to 
evidence-based practice was used (see Figure 1.) This model has six constructs: (a) assess the 
need for a change in practice, (b) link the problem interventions and outcomes, (c) synthesize the 
best evidence, (d) design a practice change, (e) implement and evaluate the change in practice, 
and (f) integrate and maintain the change in practice. 
Figure 1 
Rosswurm and Larrabee’s (1999) model for evidence-based practice. 
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Assess the Need for a Change in Practice 
In the first step of the R&L model (Pipe, Wellik, Buclida, Hansen, & Martyn, 2005); the 
need for change at the clinic is assessed. In this pediatric clinic, the three-dose HPV vaccine 
completion rate is low. Also, most of the time, the parents refuse to get their children vaccinated. 
According to Healthy People 2020 (HP2020, 2014), the target of HPV immunization is 80%. 
During each clinic visit, parents need to be encouraged to vaccinate their children, and this is 
possible only through timely counseling. Another reason for low vaccination initiation and 
completion may be due to the existing appointment system. Both telephone calls to customers 
and/or giving them an appointment card as reminders may not be effective enough due to 
patients not taking the calls or misplacing the appointment cards. This means that the staff and 
providers at the clinic need a change in practice. 
Link the Problem Interventions and Outcomes 
The second step of the R&L model is linking the problem with the intervention and its 
outcomes. Even though the HPV vaccine was introduced in 2007, the knowledge gap among 
parents and a lack of clinician recommendations are reasons for lower initiation and completion 
rates for the vaccine (CDC, 2014a). In this project the programmatic intervention is counseling 
the parents and implementing the text messaging reminder system, which should help achieve 
the desired outcome of improving the three-dose HPV vaccine’s initiation and completion rates 
by a given period of time. 
Synthesize the Best Evidence 
Synthesizing the best evidence is the third step of the R&L model. The DNP student 
conducted a literature review to examine the evidence of reasons for HPV vaccine compliance 
and the methods that improved its compliance among adolescents. The studies cited previously 
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in this paper provide the best evidence for why the project is needed at the pediatric clinic. This 
could also help realign the clinic’s practices toward the outcome of meeting the HP2020 goal of 
improving the HPV vaccine’s initiation and completion rates. 
Design a Change in Practice 
The fourth step of the R&L model is to design a change in practice. In the current 
pediatric clinic, the ineffective telephone-call reminder system and individual vaccine counseling 
not being offered during each visit could be reasons for the low HPV vaccination rates. Based on 
the evidence from this literature review, the DNP student designed a change plan to implement a 
“must counsel” rule and a text messaging reminder system. The change in practice included a 
system designed in such a way that the changes are implemented, measured, corrected, 
reimplemented (as needed), and confirmed for accuracy and efficiency to achieve the expected 
outcome of the project. 
Implement and Evaluate the Change in Practice 
Implementing and evaluating the change in practice is the fifth step. This QI project was 
implemented in a pediatric clinic at Harlingen. The DNP student educated the pediatrician, nurse 
practitioners (NPs), and other staff regarding the new text messaging reminder system and the 
importance of educating parents about HPV vaccination during each visit. They were actively 
involved in the implementation and evaluation of the process. Any changes necessary would be 
evaluated, and necessary updates to the project were made using the R&L model, going back to 
the first step of the R&L model and continuing through the steps deemed best. This ensured a 
proper evaluation and implementation of the change desired and a better outcome. 
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Integrate and Maintain the Change in Practice 
The sixth and final step is to integrate and maintain the change in practice. After the 
three-dose vaccine regimen for the targeted age group of patients was completed, the DNP 
student conducted a data analysis on the impact of counseling and the new reminder system on 
the HPV vaccination rate. If there is an improvement and outcome goals are met, then this can be 
presented to the stakeholders. The immunization nurse can implement the system of changes for 
other vaccines at the clinic, which should improve other vaccine compliance rates, too. This 
would help the clinic achieve a better rating in the community and allow it to serve as a role 
model for other providers in the area, as well as communities all over, and meet the HP2020 
goals. 
Project Design/Methods/Implementation 
Project Design 
The purpose of this evidence-based QI project was to evaluate and compare HPV vaccine 
initiation and completion rates using the prior reminder system to data from the QI project, in 
which a text message reminder system was implemented for HPV vaccine appointments. This 
was conducted at a pediatric clinic between Harlingen and San Benito, TX. The project was of a 
one group pretest–posttest design. 
Data from a random review of 100 charts of adolescents aged 9–18 years (before 
implementation) who were reminded about their HPV vaccine appointments using the prior 
system (e-mails and phone calls) were provided by the clinic’s administration from their 
electronic health record (EHR) system. For the QI project, the eligible participants were 
adolescents aged 9–18 years who had already initiated or were to start initiating the three-dose 
HPV vaccine series during the project implementation period of October 2015-April 2016. 
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Enrollees received up to three text message reminders for each appointment. They were surveyed 
once during their visit to evaluate their preference of a reminder system. 
Prior to the start of the project, the DNP student talked with the clinic’s manager about 
setting up the text messaging reminder system and presented the feasibility and cost report to the 
clinic’s administrators. Upon approval of the administrators, the text message reminder system 
was activated in the clinic’s EHR software. The text messages were sent through the EHR 
system in English (and in Spanish for those patients/parents who preferred Spanish). 
The project focused on the basic implementation plan, including conducting an 
orientation and training for the staff about the project, the HPV vaccine, and HPV-related 
diseases. The goal of the project was to implement the text messaging reminder system in the 
pediatric clinical site for 6 months, educate staff about the enrollment acknowledgement form for 
this project, and explain the additional survey at the end of each completion to evaluate the 
success of text messaging reminder system compared to prior reminder system to the staff. 
The DNP student organized and orchestrated the following: 
o trained the staff members and worked with them to select eligible adolescents 
between the ages of 9 and 18 years who could receive HPV vaccines (initiation, 
continuation, and completion) for counseling and enrolling in project, 
o trained for counseling and provided HPV vaccine information, 
 trained the vaccination nurse to counseling candidates or parents on HPV 
vaccines for all selected patients, 
 trained the medical assistants to provide patients or parents with HPV 
vaccination leaflets/education materials during counseling, either in Spanish 
or English based on the patient preferences, 
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 explained the benefits and possible risk of the HPV vaccine with the parents, 
and 
o trained the staff on the text message reminder system. 
The DNP student checked the following vaccine information: 
o accuracy, stock, and expiration date of HPV vaccines for the project; 
o vaccine delivery to candidates and data entry; 
o that all vaccines were given at the clinic after a written order from a pediatrician; 
o that all HPV vaccine doses were given at the appropriate intervals according ACIP’s 
recommendations; 
o that appropriate data logging was performed by the vaccine nurse as required by state 
and federal laws through the EHR system used in the clinic; and 
o that patients were enrolled in the reminder system to receive text message alerts for 
the next dose of the vaccine, as appropriate. 
The DNP student received vaccine updates on a weekly basis from the clinic manager, 
who tracked and updated the first, second, and third HPV-vaccine information through the EHR 
system. In the absence of the clinic manager, the clinic’s staff entered the vaccine due dates for 
each patient’s second and third HPV dose in the EHR system. The data analysis was completed 
using SPSS descriptive statistics to find out the one group pretest–posttest results and compared 
the vaccine compliance and completion rates of the HPV vaccine in (a) the preimplementation 
patients who were HPV vaccine recipients in the past year (who received telephone call and/or 
appointment card reminders) and (b) candidates who received text message reminders for their 
HPV vaccine appointments. The results of the data analysis are explained using charts and 
diagrams. 
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Inclusion criteria included (a) pediatric patients who attended the pediatric clinic, (b) 
males and females aged 9–18 years who were registered for a visit (including walk-ins), and (c) 
candidates who had never received the HPV vaccine and those who had already initiated the 
HPV vaccine series but were in line for their second and/or third doses for HPV vaccine 
completion. These patients and their parents were counseled by the pediatrician and/or the DNP 
candidate about the importance of completing the three-dose HPV vaccine series. Patients who 
accepted to be vaccinated were enrolled in the project by the DNP student and were told about 
the benefits and risks of the HPV vaccination, text messaging reminder system, agreement form, 
and the single survey at the end of a vaccination appointment. The enrolled participants were 
asked to complete the enrollment acknowledgement form (see Appendix A) while they waited 
for the visit; this form included the patient’s name (if the patient were a minor, parent’s name as 
well) and the preferred cell phone number (if the patient were a minor, then that of the parent) 
for receipt of text message reminders. The reminder messages were sent to the patient (or parent 
when the child was a minor). Patients or parents (of minors) were informed that they had the 
right to refuse or terminate the HPV vaccination at any time after the commencement of the 
project. 
Further HPV vaccine counseling was provided to parents of eligible children as needed (9 
to 18 years old). Individual counseling on the vaccine was given during the clinic visit for 
patients who were 18 years old. Counseling included information about the HPV vaccine, 
vaccine recommendations and schedules, who should be vaccinated, when and why one should 
get vaccinated, the possibility of HPV infection in sexually active teens, and important vaccine 
information such as contraindications, efficacy, risk, and allergic reactions; they were also 
counseled on the benefits of getting vaccinated or vaccinating children early. After completion of 
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the counseling, the HPV vaccination dose was administered by the nurse and recorded in the 
EMR system in the clinic by the vaccine nurse. The due dates for the second and the third HPV 
vaccine were also entered into the EMR, and text message alerts were set up. Text message alerts 
for the next HPV vaccine dose were sent to each patient on the appropriate dates.  
Each participant received two text message reminders per dose; the first message was 
sent 6 days prior to each HPV vaccine due date, and a second one was sent the day before the 
vaccine due date. A third message was sent the day after the appointment date if the candidate 
missed the vaccination appointment. The reminder messages were written as follows for the 
three doses of vaccine. “You are (Your child is) (past) due for your vaccine appointment. Please 
call the pediatric office number at (xxx) xxx-xxx regarding the vaccine appointment.” Each 
week, the DNP student analyzed the vaccine records provided by the office manager and tallied 
them by entering the vaccine data into a Microsoft Excel spreadsheet in order to track the 
vaccine completion status. 
Goals, Objectives, and Expected Outcomes 
The goals, objectives, and expected outcomes are shown in detail in Table 1. The 
expected outcome of interest is the success of text message reminders, which should show an 
increase in the rates of HPV vaccine initiation and series completion at the selected pediatric 
clinic postimplementation compared to preimplementation. Another variable of interest is the 
increase in the number of patients finding the text messaging reminder system beneficial 
compared to the prior reminder system. 
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Table 1 
Goals, Objectives, and Expected Outcomes 
Goal – To train the pediatric clinic staff about the importance of HPV and its prevention by the HPV vaccine 
Objective Expected Outcome 
At the beginning of the project, an education session will 
be conducted among the staff in the pediatric clinic, 
emphasizing the importance of HPV and the HPV 
vaccine and to improve vaccination compliance. 
Eighty percent of the pediatric clinic staff will attend the 
meeting; Eighty percent of the staff will verbalize an 
understanding of the education session on HPV and the 
HPV vaccine. 
Educate providers about the importance of implementing 
the text messaging reminder system for HPV vaccine 
compliance 
Eighty percent of the pediatric clinic staff will verbalize 
an understanding of the importance of the text 
messaging reminder system. 
Goal – To implement the text messaging reminder system into the pediatric practice clinic  
Objective Expected Outcome 
The text messaging reminder system will be implemented 
into the practice in the clinic and checked for any flaws. 
The reminder system will be implemented by the end of 
first week after project initiation, and the staff will be 
trained on using the new reminder system. Eighty 
percent of the staff will be able to use the reminder 
system without any problems. 
Goal – Parents and adolescents will be educated about HPV vaccination and the text messaging reminder 
system 
Objective Expected Outcome 
The parents will be counseled and given information 
about HPV vaccination and the text messaging reminder 
system. 
Eighty percent of the parents will verbalize an 
understanding of the importance of giving the HPV 
vaccination to their children. 
Eligible candidates and/or parents (of minors) will have 
to sign the enrollment acknowledgement form and 
provide their cell phone number. 
Eighty percent of the candidates and/or parents will sign 
and enroll for the HPV vaccine. 
Text message reminders will be sent for each HPV 
vaccine dose for those enrolled. 
Eighty percent of the candidates will receive the text 
message reminders. 
Vaccine rates will be analyzed each month in the EHR 
system. 
Significant improvement in the HPV vaccine initiation 
and completion rates at the clinic 
Patients/parents will be provided with the survey form 
(see Appendix G) at end of the vaccine dose. 
Eighty percent of candidates/parents will complete the 
survey 
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Description of the Group, Population, or Community 
 This QI project was conducted in an outpatient pediatric clinic situated between 
Harlingen and San Benito, TX. The clinic, being close to the border of Harlingen and San 
Benito, benefits from patients from both cities. The 2010 census (U.S. Census Bureau, 2015) 
showed that Harlingen had a population of 64,849, of which approximately 79.5% were 
Hispanic/Latino, 52.2% were female, 8.6% were children under the age of 5 years, and 30.4% 
were under 18. The population of San Benito was 24,253, of which approximately 90.7% were 
Hispanic/Latino, 51.6% were female, 9.4% were children under the age of 5 years, and 33.2% 
were under 18. The community of interest included girls and boys between the ages of 9 and 18 
years; however, the clinic sees girls and boys up to 18 years of age. The pediatric clinic was 
established in 2006, and it provides care for pediatric patients, from newborns to 18 years of age. 
This clinic has a case load of approximately 60–75 patients per day, and it varies each day. The 
physician and nurse practitioner see patients based on appointments. Walk-in patients are also 
accepted. The goal of this pediatric clinic is to provide the best standard of care to each patient, 
regardless of gender or sexual identity, racial background, age, or financial status. It takes private 
insurance, Medicare, and Medicaid. One of the policies of this clinic is to maintain the standard 
of confidentiality and also to create an environment of trust and respect among the staff and 
patients. Services provided by this clinic are annual wellness examinations, sick visits, sports 
physicals, immunizations, health education, minor non-surgical procedures, routine laboratory 
work, and hearing tests. 
Ethics and Human Subjects Protection 
The goal of this QI project is to improve patient compliance with the three-dose HPV 
vaccine series and included point-of-care education by providing educational pamphlets on HPV 
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to the parents and adolescents, which helps to initiate and complete the three-dose series of the 
HPV vaccine. The project involved human subjects but did not involve any research activities on 
the subjects. The DNP student did not collect any health history from the candidates and/or 
parents other than allergies to any medications or vaccinations. 
Confidentiality was maintained throughout the QI project. Patient information (including 
all personal identifiers) was maintained in the pediatric office per the clinic’s policies. All data, 
including private patient information, were handled by the DNP student at the clinic only, and 
patient information was kept confidential throughout the completion of the project (paper, text 
message, etc.) and was complete compliant with the Health Insurance Portability and 
Accountability Act (HIPAA). 
Results 
Outcomes 
Demographic data. A random review of data of the 100 charts of vaccine-eligible 
adolescents obtained from the clinic administrators suggested that the mean age of adolescents in 
the practice was 12.49 years (SD = 2.61) and the age range was 9–18 years (see Table 4).  
At the time of the text-messaging system implementation, there were 49 participants 
between 9 and 17, with mean age of 12.22 years (SD = 1.83; see Table 5). The majority of 
participants were 11 and 12 years old (15 and 11 participants, respectively), or about 53% of all 
participants. Among all participants, 53.1% (n = 26) were females, and 46.9 % (n = 23) were 
males (see Tables 8). Of all the participants, 47 (96%) were Hispanic, 1 (2%) was White, and 1 
(2%) was classified as other.  
Data analysis comparison of prior system and text messaging system. Based on the analysis 
of the prior system data (n = 100), 11% completed the three-dose HPV vaccine series.  In 
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comparison, 46.9% (23) participants from the text messaging system group (n = 49) completed 
the vaccine series. A summary of the findings is given in Table 2 below. 
Table 2 
 
Summary of Findings (Prior vs. Text Messaging Systems) 
 
 Age (years) 
Mean (SD) Males/Females 
3-dose HPV Vaccination Series 
Completed Initiated No Shows 
Pre-test 
(n=100) 
12.49 (2.61) 50/50 11% 6% 83% 
Post-test 
(n=49) 
12.22 (1.83) 23/26 23(46.9%) 26(53.1%) 0% 
 
Both groups showed a better completion rate among females (8 and 15 participants respectively) 
compared to males (three males and eight males respectively). Among both groups, those who 
initiated the series were 6% and 53.1% (26) respectively. Data analysis also showed the 
following: Two males and 2 females from the prior system group and 5 (10.2%) participants (4 
males, 1 female), from the text messaging system group, received only the first vaccine of the 
HPV vaccine series. The prior system group had one male and one female, while the text 
messaging system group had 12 (24.5%) participants (five males, seven females) who received 
the first two vaccines of the series. 
Eighty-three participants (44 males and 39 females) from the prior system group and 
none from the text message system group were “no shows” for the vaccine series. However, nine 
(18.4%) participants (six males, three females) in the text message system group were “no 
shows” for the second or third vaccine appointment (i.e., who had received at least one vaccine 
with a text message reminder; see Table 3 below). 
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Table 3 
 
Analysis of All Completed Surveys 
 
Summary 
Cases 
Valid Missing Total 
N Percent N Percent N Percent 
Total cases with completed 
surveys 
30 61.2% 19 38.8% 49 100.0% 
Total cases 
with completed 
surveys by 
gender 
Male (0) 13 26.5% 10 20.4% 49 100.0% 
Female (0) 17 34.7% 9 18.4% 49 100.0% 
 
Text messaging system survey analysis. Only participants who were enrolled and 
completed at least one of their scheduled vaccine appointments after receiving text message 
reminders were requested to complete the survey. Of 49 total participants, 30 valid surveys 
(61.2%) were analyzed. Fifty-seven percent of the respondents were female.  
For questions relevant to counseling (Q1a and Q1b), twenty eight (93%) survey 
respondents responded that counseling improved knowledge about the vaccine. The decision to 
get vaccinated was effected by counseling for 63% respondents; 27% responded that counseling 
did not influence the vaccine decision (see Table 9 and Table 10). 
The text message reminders from the clinic were received by all but one respondent.  
That one respondent mentioned in the comments that there was no signal at her residence. All 
but one respondent responded that the text reminder was helpful in remembering to attend the 
appointment (Q2b, see Table 12). Eighty percent of all the respondents responded that they 
preferred text message reminders to other forms of reminders (Q2d, see Table 14). 
Evaluating the comments, 24 (80%) respondents commented positively on text message 
reminders. Four (13%) respondents had no comments, while one commented that e-mail or 
phone-call reminders were okay (Q2e, see Table 15). Among the comments, most responses 
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were “have easy access to phones,” “cannot take phone calls at work,” “text messages are 
easier,” “can be easily retrieved,” “good reminder since I always forget.” A few other comments 
said “text/email/phone calls are very helpful,” and one comment said “no good signal at home.” 
The majority of the participant comments indicated that text messaging was convenient and 
easier compared to other forms of reminders. 
Resources, Facilitators, and Barriers. 
The resources used during this QI project were office supplies, an office computer, an 
office telephone, and time. The DNP student used the CDC’s HPV vaccine information 
statement to counsel the parents, and a copy of this statement was provided to each parent who 
participated in this project. Time was needed to counsel parents on the HPV vaccine information 
and to gather and analyze the data to obtain the results of the project. All staff members in the 
selected pediatric clinic were identified as key stakeholders. The staff members who facilitated 
this QI project were the pediatrician, pediatric NP, nurses, and front-desk clerk, who were in 
direct contact with the patients and family members. The manager of the clinic was the chief 
facilitator during the entire project. The DNP student conducted weekly meetings with the clinic 
manager for ongoing plans, updates, and feedback. When the DNP student was not in the clinic, 
she encouraged the staff to send text messages to the parents in a timely manner and provide the 
survey form to each patient after the vaccination was completed.  
Some of the barriers to the project included language (some of the patients knew only 
Spanish), time constraints, patient compliance with appointments, and the project’s duration. 
Spanish-speaking patients and families were helped by the office’s nurse aides to assure effective 
communication. Even though the staff members were well trained in terms of the implementation 
of this project, the workflow at the clinic was disrupted soon after implementation. This 
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happened when one of the medical assistant was on leave. Getting updated and working cell 
phone numbers from participants was also another challenge faced by the DNP student while 
enrolling the participants in this project. Another potential barrier was that a few of the subjects 
were not showing up for scheduled appointments due to financial problems (according to the 
clinic staff) which could have affected the outcome of the project. The actual project duration 
was shorter than the desired time for completing the project. Due to this, it was not possible to 
evaluate the completion rates for those who initiated the vaccine series at a time after the 
expected implementation time (i.e., the third dose for the initiators was completed 6 months after 
the initial vaccine date). 
Methods to address these barriers included the DNP student using the office clerks to 
translate the information on HPV vaccine: Pamphlets were provided in Spanish to Spanish-
speaking patients. To save time, there was a need for a plan to use the patients’ waiting time after 
registration to enroll and counsel the patients. The efforts of the clerks and nurses were important 
to completing that plan maintaining efficiency. Prior patient compliance issues in terms of 
keeping appointments made exit counseling even more important at the end of each patient visit. 
Discussion/Interpretations 
The first goal—training the pediatric clinic staff in terms of the importance of HPV and 
its prevention using the HPV vaccination—was fully met. All of the pediatric staff verbalized an 
understanding of the education session on HPV and the HPV vaccine. The pediatrician and staff 
verbalized their understanding of the importance of the text messaging reminder system. The 
increase in knowledge among the clinic’s staff was not measured, as the DNP student’s main 
goal was to evaluate the text messaging system and its feasibility. 
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 The second goal regarded implementing the text messaging system at the pediatric clinic 
so that all staff members were able to use the reminder system without any problems. The staff 
also verbalized that it was easy and convenient to use the text messaging system. According to 
staff members, it took less time to send a text message than make a phone call to a 
parent/subject. 
 The third goal of educating the parents and adolescents about HPV vaccination and the 
text message reminder system was evaluated using the survey. From the completed surveys (see, 
Table 9), most responses among the vaccine completion status groups showed that HPV-vaccine 
counseling helped participants understand the vaccine and its benefits (see Table 10). However, 
two female subjects indicated that counseling did not help. 
 The data from both the prior and text messaging systems in the current QI project 
indicated that text message reminders had a bigger impact on the participants’ initiating (4% and 
10.2%, respectively) and completing (11% and 46.9%, respectively) the vaccine series than e-
mails and telephone reminders. The results observed in this project are in accordance with the 
results from a few other studies. Kharbanda et al. (2011) found that text message reminders were 
an effective intervention to increase timely receipt of HPV 2 or HPV 3 vaccines. The findings 
from Matheson et al.’s (2014) study showed improvement in the HPV series completion rate as a 
result of text message reminders. 
The positive impact of text message reminders on the improved HPV vaccine coverage in 
this QI project was also confirmed through the survey data, which showed that 80% of the 
respondents preferred text message reminders over other reminders. This could be due to the 
increase in use of smartphones among the participants. Eighty percent of the parents reported 
that they would prefer text messaging over e-mail or phone-call reminders, since they had easy 
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access to cell phones and text messages did not cause any interference when they were at work. 
When the clinic staff was asked about how easy or difficult it was to use phone-call and e-mail 
reminders compared to text message reminders, staff members said that the text messaging 
reminder system was easier and saved more time. The clinic administrators found this system to 
be beneficial and expressed interest in continuing the text message reminder system for all of 
their clinic’s appointments.  
Suggestions/Future Recommendations  
The project results suggest that the clinic can use the text messaging system to make 
appointments for all of its patients, thereby increasing revenue for the clinic while improving the 
health of its patients through timely appointments. The clinician can actively practice 
preventative care and thus reduce the burden on state-funded programs like Medicare and 
Medicaid. The staff can also use the time saved by not making phone calls to schedule 
appointments for other tasks at the clinic. Moreover, since most parents may be at work during 
the day, text messages will be more appropriate for a majority of the patients, based on the 
results of the survey. 
 Two limitations of the study were the small sample size and the fact that the study only 
examined one clinic. Future implementation projects could be conducted in larger, more 
geographically diverse populations, for longer time periods, and at multiple clinics for 
generalizability. This project also did not make use of reminders for appointments for any 
subjects who rescheduled their appointments. 
Conclusion 
The HPV vaccine is an important vaccine that is available in three doses and prevents 
certain cancers. The results of this QI project showed that text message reminders were effective 
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in promoting timely receipt of the three-dose HPV vaccine series. The text messaging reminder 
system could be used as a standard reminder system for other vaccines and appointments at this 
pediatric clinic and other clinics. This would help our communities keep vaccine-preventable and 
other diseases in check and maintain health, thus getting closer to reaching the HP2020 goal. The 
results of this project were presented and discussed with the pediatrician, the NPs, and other staff 
members at the clinic. The project will be presented during the Scholarly Presentation Day at the 
University of Massachusetts at Amherst, College of Nursing. 
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Table 4 
 
Frequency of Participant Age (Prior vs. Text Messaging Systems) 
 
Frequencies 
Participant Age (years) Prior System Text Messaging System 
N 100 49 
Mean 12.49 12.22 
Std. Error of Mean 12.00 0.26 
Median 11 12.00 
Mode 11 11 
Std. Deviation 2.611 1.829 
Variance 6.818 3.344 
Range 9 8 
Minimum 9 9 
Maximum 18 17 
 
Note: Multiple modes exist for the median value for the prior system and the smallest value is 
shown. 
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Table 5 
 
Frequency of Participant Age (Prior vs. Text Messaging Systems) 
 
Participant Age 
(years) 
Prior System Text Messaging System 
Frequency Percent Frequency Percent 
9 12 12.0 2 4.1 
10 13 13.0 4 8.2 
11 17 17.0 15 30.6 
12 17 17.0 11 22.4 
13 8 8.0 4 8.2 
14 12 12.0 6 12.2 
15 5 5.0 5 10.2 
16 5 5.0 1 2.0 
17 5 5.0 1 2.0 
18 6 6.0 0 0.0 
Total 100 100.0 49 100.0 
 
 
Table 6 
 
Frequency Table of Participant Gender (Prior vs. Text Messaging Systems) 
 
Gender 
Prior System Text Messaging System 
Frequency Percent Frequency Percent 
Female (1) 50 50.0 26 53.1 
Male (0) 50 50.0 23 46.9 
Total 100 100.0 49 100.0 
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Table 7 
 
Frequency of Vaccine Series Completion Status vs. Gender (Prior vs. Text Messaging Systems) 
 
Prior System 
Gender 
Total 
Male (0) Female (1) 
No Shows (0) 44 39 83 
Received 1st Vaccine in Series (1) 2 2 4 
Received 1st and 2nd Vaccines in Series (2) 1 1 2 
Completed Vaccine Series (3) 3 8 11 
Total 50 50 100 
Text Messaging System 
Gender 
Total 
Male (0) Female (1) 
No Show (0) 0 0 0 
Received 1st Vaccine in Series (1) 4 1 5 
Received 1st vaccine prior to project and received 
2nd & 3rd vaccine with TM reminders to complete 
series (1C3) 
5 5 10 
Received 1st and 2nd vaccine in series but yet to 
complete series (2Y) 
5 7 12 
Completed Vaccine Series (3) 3 10 13 
Received 1st series prior to project and received 2nd 
vaccine with TM reminders, but no show for 
completion (C2) 
6 3 9 
Total 23 26 49 
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Table 8 
 
Keys for Vaccine Series Completion Status 
 
0 No Show 
1 Received only first vaccine in the series 
2 Received the first two vaccines in the series 
3 Completed the vaccine series 
2C3 
Completed two vaccines prior to the project and completed the series with text messaging (TM) 
reminders 
2CY 
Completed two vaccines prior to project but has yet to come for a future appointment to complete the 
series with TM reminders 
2C Completed two vaccines prior to project but was a no show for the last vaccine appointment 
1C3 Completed the first vaccine prior to the project and completed the series with text TM reminders 
1CY 
Completed the first vaccine prior to the project, received the second vaccine with TM reminders, but 
has yet to come for a future appointment to complete the series. 
C2 
Received first series prior to the project and received the second dose with TM reminders but was a no 
show for completion (C2) 
CY 
Completed the first vaccine prior to the project but has yet to come for a future second vaccine 
appointment 
1C 
Completed the first vaccine prior to the project but was a no show for the second vaccine appointment 
with TM reminders  
2Y 
Received the first two vaccines in the series with TM reminders but has yet to come for a future third 
vaccine appointment to complete the series 
1Y 
Received the first vaccine in the series with TM reminders but has yet to come for a future second 
vaccine appointment 
Y Has yet to come for a future first vaccine appointment 
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Table 9 
 
Q1a vs. Vaccine Series Completion Status vs Gender 
 
Gender  
Q1a - Did you learn more about the 
vaccine and its benefit? 
Total No (0) Yes (1) 
Male 
(0) 
Vaccine Series 
Completion 
Status 
1  1 1 
1C3  4 4 
2Y  5 5 
3  3 3 
Total  13 13 
Female 
(1) 
Vaccine Series 
Completion 
Status 
1C3 1 3 4 
2Y 0 6 6 
3 1 6 7 
Total 2 15 17 
Total 
Vaccine Series 
Completion 
Status 
1 0 1 1 
1C3 1 7 8 
2Y 0 11 11 
3 1 9 10 
Total 2 28 30 
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Table 10 
 
Q1b vs. Vaccine Series Completion Status vs. Gender 
 
Gender  
Q1b - Did counseling about the vaccine 
affect your decision to get vaccinated? 
Total No (0) Yes (1) 
Male 
(0) 
Vaccine Series 
Completion 
Status* 
1 0 1 1 
1C3 2 2 4 
2Y 3 2 5 
3 1 2 3 
Total 6 7 13 
Female 
(1) 
Vaccine Series 
Completion 
Status* 
1C3 1 3 4 
2Y 2 4 6 
3 2 5 7 
Total 5 12 17 
Total 
Vaccine Series 
Completion 
Status* 
1 0 1 1 
1C3 3 5 8 
2Y 5 6 11 
3 3 7 10 
Total 11 19 30 
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Table 11 
 
Q2a vs. Vaccine Series Completion Status vs. Gender 
 
Gender  
Q2a - Did you receive a text message 
from the clinic reminding you of your 
appointment? 
Total No (0) Yes (1) 
Male 
(0) 
Vaccine Series 
Completion 
Status* 
1 0 1 1 
1C3 0 4 4 
2Y 1 4 5 
3 0 3 3 
Total 1 12 13 
Female 
(1) 
Vaccine Series 
Completion 
Status* 
1C3 1 3 4 
2Y 0 6 6 
3 0 7 7 
Total 2 15 17 
Total 
Vaccine Series 
Completion 
Status* 
1 0 1 1 
1C3 1 7 8 
2Y 1 10 11 
3 0 10 10 
Total 2 28 30 
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Table 12 
 
Q2b vs. Vaccine Series Completion Status vs. Gender 
 
Gender  
Q2b - Was the text message reminder 
helpful for you in remembering to come 
for your visit?  
Total No (0) Yes (1) 
Male 
(0) 
Vaccine Series 
Completion 
Status* 
1  1 1 
1C3  4 4 
2Y  5 5 
3  3 3 
Total  13 13 
Female 
(1) 
Vaccine Series 
Completion 
Status* 
1C3 1 3 4 
2Y 0 6 6 
3 0 7 7 
Total 1 16 17 
Total 
Vaccine Series 
Completion 
Status* 
1 0 1 1 
1C3 1 7 8 
2Y 0 11 11 
3 0 10 10 
Total 1 29 30 
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Table 13 
 
Q2c vs. Vaccine Series Completion Status vs. Gender 
 
Gender  
Q2c - Have you received reminders in the 
form of telephone calls or appointment 
cards for the HPV vaccine appointments 
or any previous vaccine or clinic 
appointments?  
Total No (0) Yes (1) 
Male 
(0) 
Vaccine Series 
Completion 
Status* 
1 0 1 1 
1C3 0 4 4 
2Y 1 4 5 
3 0 3 3 
Total 1 12 13 
Female 
(1) 
Vaccine Series 
Completion 
Status* 
1C3 2 2 4 
2Y 1 5 6 
3 2 5 7 
Total 5 12 17 
Total 
Vaccine Series 
Completion 
Status* 
1 0 1 1 
1C3 2 6 8 
2Y 2 9 11 
3 2 8 10 
Total 6 24 30 
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Table 14 
 
Q2d vs. Vaccine Series Completion Status vs. Gender 
 
Gender  
Q2d - Did you learn more about the 
vaccine and its benefit?  
Total No (0) Yes (1) 
Male 
(0) 
Vaccine Series 
Completion 
Status* 
1 0 1 1 
1C3 1 3 4 
2Y 0 5 5 
3 0 3 3 
Total 1 12 13 
Female 
(1) 
Vaccine Series 
Completion 
Status* 
1C3 2 2 4 
2Y 2 4 6 
3 1 6 7 
Total 5 12 17 
Total 
Vaccine Series 
Completion 
Status* 
1 0 1 1 
1C3 3 5 8 
2Y 2 9 11 
3 1 9 10 
Total 6 24 30 
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Table 15 
 
Q2e (Comments) vs. Vaccine Series Completion Status vs. Gender 
 
Gender 
Q2e (Comments About Text Messaging 
Reminders) 
Total 
Do Not 
Favor (0) 
Do Favor 
(1) 
Does not 
Matter/No 
Comments (9) 
Male 
(0) 
Vaccine Series 
Completion Status* 
1  1 0 1 
1C3  2 2 4 
2Y  5 0 5 
3  3 0 3 
Total  11 2 13 
Female 
(1) 
Vaccine Series 
Completion Status* 
1C3 1 2 1 4 
2Y 1 5 0 6 
3 0 6 1 7 
Total 2 13 2 17 
Total 
Vaccine Series 
Completion Status* 
1 0 1 0 1 
1C3 1 4 3 8 
2Y 1 10 0 11 
3 0 9 1 10 
Total 2 24 4 30 
 
* Please refer to Table 8 for Keys for “Vaccine Series Completion Status” 
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Appendix A 
HPV VACCINATION IMPROVEMENT PROJECT 
Enrollment Acknowledge Form 
Dear Patient/Parent, 
This is a quality improvement (QI) project that a Doctor of Nursing Practice (DNP) 
student is conducting at this clinic from _____ 2015 to _____ 2016 to determine if a text 
messaging reminder system would have a significant effect on initiating and completing the 
Human Papilloma Virus (HPV) vaccination series of 3 doses. Please read the acknowledgement, 
and once you understand and agree to enrollment, sign and date the form. You agree that: 
 Once enrolled, you will receive 2 to 3 alerts in the form of text messages through your 
mobile phone. 
o You will receive text messages only if you have the text messaging feature through 
your mobile-phone carrier (e.g., AT&T, Verizon, etc.). 
o The clinic or the DNP student will not be responsible for any charges you might incur 
from your carrier, which will be paid entirely by you. 
 Should your mobile phone number change, please update the number with the clinic so your 
records can be updated. 
 The vaccine doses will be determined as recommended by the US Centers for Disease 
Control’s (CDC) Advisory Committee on Immunization Practices (ACIP) guidelines and 
your allergy history. 
 Your personal and private health information records will never leave the clinic, and 
complete confidentiality will be maintained, as required by HIPAA guidelines and per the 
clinic’s personal information disclosure policies. 
 You have the right to withdraw yourself (or your child) from the project at any time. 
 You can still be a customer at the clinic and obtain the HPV vaccine doses even if you decide 
not to enroll or withdraw from the project. 
 
I, _______________________________________________, understand and agree to enroll in 
this QI project. I understand that I have the right to withdraw myself/ my child from the project 
anytime. 
 
 Full name of candidate: ____________________________________________________ 
 Signature of candidate (if an adult): ___________________________________________ 
 
If candidate is a minor 
 Full name of parent: _______________________________________________________ 
 Signature of parent: _______________________________________________________ 
 
Date: _______________ 
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Appendix B 
HPV VACCINATION IMPROVEMENT PROJECT 
Survey 
 
Please complete the following survey questions as truthfully possible. Your answers will be used 
only to evaluate the outcome of the project. 
 
1. Counseling 
a. Did you learn more about the vaccine and its benefit? 
Yes  No  
 
b. Did counseling about the vaccine affect your decision to get vaccinated? 
Yes  No  
 
2. Text Message Reminders 
a. Did you receive a text message from the clinic reminding you of your appointment? 
Yes  No  
 
b. Was the text message reminder helpful for you in remembering to come for your 
visit? 
Yes  No  
 
c. Have you received reminders in the form of telephone calls or appointment cards for 
the HPV vaccine appointments or any previous vaccine or clinic appointments? 
Yes  No  
 
d. Would you prefer text message reminders better than other forms of reminders? 
Yes  No  
 
e. Why did you choose your answer for question 2.d? 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 
Thank you very much for taking the time to complete this survey. Please hand this form 
back to the clinic staff member assisting you during this visit. 
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Appendix C 
PROYECTO DE MEJORA DE VACUNACIÓN VPH 
Encuesta 
 
Por favor complete las siguientes preguntas de la encuesta la verdad posible. Sus respuestas se 
utilizarán para evaluar el resultado del proyecto. 
 
1. Consejería 
a. ¿Aprendiste más sobre la vacuna y sus beneficios? 
Si  No  
 
b. ¿Hizo de asesoramiento sobre el efecto de la vacuna contra la decisión de vacunarse? 
Si  No  
 
2. Recordatorios de mensaje de texto 
a. ¿Ha recibido un mensaje de texto de la clínica de recordarle de su cita? 
Si  No  
 
b. ¿Fue el aviso de mensaje de texto útil para ti en recuerdo a su visita? 
Si  No  
 
c. ¿Ha recibido recordatorios en forma de llamadas telefónicas o cartas de 
nombramiento para las citas de la vacuna de VPH o cualquier vacuna anterior o citas 
de la clínica? 
Si  No  
 
d. ¿Preferiría mejor que otras formas de recordatorios de mensaje de texto? 
Si  No  
 
e. Por qué elegiste tu respuesta para la pregunta “2. ¿d”? 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 ________________________________________________________________________ 
 
Muchas gracias por tomarse el tiempo para completar esta encuesta. Por favor, mano esta 
forma volver al miembro del personal del clínica que le ayudó durante esta visita. 
 
